Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 149 Lymphoma, Large B-Cell, Diffuse 114 Lymphoma, Non-Hodgkin 110 Precursor Cell Lymphoblastic Leukemia-Lymphoma 106 Leukemia 81 Hodgkin Disease 81 Small Cell Lung Carcinoma 79 Leukemia, Myeloid, Acute 73 Burkitt Lymphoma 69 Lymphoma, Follicular 67 Lymphoma, Mantle-Cell 65 Lung Neoplasms 60 Lymphoma, Large-Cell, Immunoblastic 54 Leukemia, Lymphocytic, Chronic, B-Cell 47 Recurrence 40 Multiple Myeloma 39 Lymphoma, B-Cell, Marginal Zone 36 Neuroblastoma 33 Congenital Abnormalities 29 Carcinoma, Non-Small-Cell Lung 28 Lymphoma, B-Cell 25 Myelodysplastic Syndromes 24 Lymphoma, Large-Cell, Anaplastic 23 Lymphoma, Extranodal NK-T-Cell 23 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22 Brain Neoplasms 22 Sarcoma 21 Ovarian Neoplasms 21 Lymphoma, T-Cell, Peripheral 20 Central Nervous System Neoplasms 20

Interventions

Radiotherapy 1 Etoposide 1 Drug Therapy 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Extensive Small Cell Lung Cancer × Etoposide × Clear all

NCT07083375 2025-07-24

QL1706

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting

Extensive Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡